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Early treatment of rheumatoid arthritis (RA)
results in more effective disease suppression
and can be key to a successful patient
response. However, not all people who
exhibit early synovitis develop RA; for
example, in some, synovial inﬂammation
resolves spontaneously.1 The factors that
drive RA development remain unclear and
clinical tools to predict RA development are
imperfect.
Tenascin-C is a proinﬂammatory matrix
molecule that is absent from healthy joints
but highly expressed in the joints of patients
with RA.2 3 We identiﬁed an immunodomi-
nant peptide in citrullinated tenascin-C,
cTNC5, antibodies against which are
detected in around half of the patients with
RA, and can be found years before disease
onset in some individuals.4 Here, we sought
to determine if anti-cTNC5 antibodies can
discriminate among people with early syn-
ovial inﬂammation those who develop RA
and those with other outcomes.
Sera from 263 patients in the Birmingham
early arthritis cohort were analysed. Patients
were disease-modifying antirheumatic drug
(DMARD) naïve with clinically apparent syno-
vitis of ≥1 joint and with inﬂammatory joint
symptoms of ≤3 months’ duration. Patients
were followed for 18 months to ensure devel-
opment of full disease phenotype and to
allow any resolving arthritis time to resolve.
At 18 months, patients were assigned to the
following outcome categories: persistent RA
according to the American College of
Rheumatology (ACR) 2010 criteria5 (RA,
n=101), persistent non-RA arthritis (PNRA,
n=66) and resolving arthritis (no clinically
apparent joint swelling, no DMARD/steroid
use in the previous 3 months, n=96).
Demographic and clinical parameters were
recorded, and patients with RA divided into
anti-cyclic citrullinated peptide (anti-CCP)
antibody positive and negative subsets.6 7
Antibodies recognising cTNC5 or the non-
citrullinated control peptide (rTNC5) were
analysed by ELISA as described.4
Anti-cTNC5 antibodies were found in
40.6% of people with early synovitis who
went on to develop RA, but were detected in
a low proportion of people who developed
PNRA (6.1%), or whose disease resolved
(3.1%). No signiﬁcant antibody response
to rTNC5 was detected (p=0.527) (table 1,
see online supplementary ﬁgure S1).
Anti-cTNC5 antibodies were signiﬁcantly
more prevalent in anti-CCP antibody positive
compared with anti-CCP antibody negative
patients with RA (81.3% vs 3.8%, p<0.0001)
(table 1). Anti-cTNC5 antibody levels were
higher in patients with anti-CCP antibody-
positive RA (193.1±449.8 arbitrary units
(AU)) compared with patients with anti-CCP
antibody-negative RA (3.56±3.30 AU), PNRA
(19.42±122.7 AU) and resolving arthritis
(6.60±28.02 AU) (ANOVA p<0.0001). While
anti-cTNC5 was not better at predicting the
development of RA than anti-CCP antibody
(speciﬁcity; sensitivity: 40.6%; 95.7%
(cTNC5), 47.5%; 98.8% (CCP)), anti-cTNC5
did detect a subset of people who developed
RA who were not anti-CCP antibody positive
(3.8%). Patients with anti-cTNC5 antibody-
positive RA were more frequently anti-CCP
antibody and rheumatoid factor (RF) positive
than anti-cTNC5 antibody-negative patients
(table 2).
Together these data reveal that detection
of anti-cTNC5 antibodies in the sera of
people with early synovitis is associated with
the development of RA. While similar
numbers of people who developed RA were
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positive for anti-cTNC5 antibodies, as were positive for
anti-CCP antibodies, these two groups did not entirely
overlap; we identiﬁed a subset of anti-CCP antibody
negative, anti-cTNC5 antibody positive patients (3.8%).
This study therefore does not support replacing CCP
analysis with cTNC5 analysis to accurately predict which
patients presenting with early joint inﬂammation will go
on to develop RA. However, a combined analysis of CCP,
cTNC5 and other citrullinated antigens may increase
the number of people who can be diagnosed with RA at
this early stage. Although a small proportion of the total
patient number, when translated into the number of
people who might otherwise be missed, this could bring
signiﬁcant clinical beneﬁt.
Analysis of distinct subsets of antibodies recognising
different citrullinated peptides (anti-citrullinated
peptide antibodies, ACPA) can yield information that is
not possible to derive using artiﬁcial CCP peptides to
detect ACPA. Arising before overt clinical symptoms,
ACPA have the potential to reveal insights into disease
aetiology. For example, gene/environment (major histo-
compatibility complex shared epitope and smoking)
interactions are strongest in people who are dual positive
for antibodies against citrullinated α-enolase and for
Table 1 Demographic, clinical and laboratory characteristics of patients in each outcome group
Anti-CCP negative
RA (n=53)
Anti-CCP positive
RA (n=48)
Persistent non-RA
(n=66)
Resolving arthritis
(n=96) p Value
Female, n (%) 27 (50.9) 31 (64.6) 37 (56.1) 46 (47.9) 0.274
Age (years) 55.6±15.7 55.5±14.4 52.1±18.9 45.9±16.8 <0.0001
Symptom duration (days) 52.4±21.4 55.3±21.7 56.4±21.5 45.3±20.8 0.005
CRP (mg/dL) 10 (0–39) 17.5 (6–43.8) 20.5 (7.5–35.3) 7 (0–17) <0.0001
ESR (mm/hour) 18 (11.5–44.5) 27.5 (18.3–51.3) 21.5 (7.8–45.8) 12.5 (5–27) <0.0001
DAS28 (CRP) 4.4±1.4 4.4±1.4 3.6±1.2 2.8±1.3 <0.0001
DAS28 (ESR) 4.6±1.5 4.7±1.6 3.6±1.8 2.9±1.5 <0.001
Smoking, n (%) 0.07
Ever smoker 28/49 (57.1) 27/47 (57.4) 26/64 (40.6) 35/89 (39.3)
Never-smoker 21/49 (42.9) 20/47 (42.6) 38/64 (59.4) 54/89 (60.7)
Anti-CCP positive, n (%) 0 (0) 48 (100) 1 (1.5) 1 (1.0) <0.0001
RF IgG positive, n (%) 9 (17) 44 (91.7) 5 (7.6) 10 (10.4) <0.0001
RF IgA positive, n (%) 7 (13.2) 26 (54.2) 5 (7.6) 10 (10.4) <0.0001
Anti-cTNC5 positive, n (%) 2 (3.8) 39 (81.3) 4 (6.1) 3 (3.1) <0.0001
Anti-rTNC5 positive, n (%) 1 (1.9) 1 (2.1) 3 (4.5) 1 (1.0) 0.527
Data are shown as number (percentage), mean±SD, or median (IQR) as appropriate. Comparisons have been performed with χ2, analysis of
variance (ANOVA) and Kruskal-Wallis tests for categorical, parametric continuous and non-parametric continuous data, respectively.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; cTNC, citrullinated tenascin-C; DAS, disease activity score; ESR, erythrocyte
sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor.
Table 2 Characteristics of patients with RA with and without anti-cTNC5 antibodies
Anti-cTNC5 negative
RA (n=60)
Anti-cTNC5 positive
RA (n=41) p Value
Female, n (%) 33 (55) 25 (60.1) 0.682
Age (years) 55.2±16.1 56.1±13.3 0.785
Symptom duration (days) 52.3±21.5 56±21.5 0.400
CRP (mg/dL) 10.5 (0–43) 18 (6–39) 0.062
ESR (mm/hour) 18 (11–45) 25 (19–46) 0.372
DAS28 (CRP) 4.26±1.4 4.55±1.4 0.320
DAS28 (ESR) 4.51±1.5 4.82±1.6 0.320
28 TJC 7.22±6.5 9.1±10.4 0.267
28 SJC 7.6±7.2 6.9±5.5 0.595
Smoking, n (%)
Ever smoker 34/56 (60.7) 21/40 (52.5) 0.682
Never-smoker 22/56 (39.3) 19/40 (47.5) 0.374
Anti-CCP positive, n (%) 9 (15) 39 (95.1) <0.0001
RF IgG positive, n (%) 16 (26.7) 37 (90.2) <0.0001
RF IgA positive, n (%) 10 (16.6) 23 (56.1) <0.0001
Data are shown as number (percentage), mean±SD, or median (IQR) as appropriate. Comparisons have been performed with χ2, Student’s
t-test and Mann Whitney U test for categorical, parametric continuous and non-parametric continuous data, respectively.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; cTNC, citrullinated tenascin-C; DAS, disease activity score; ESR, erythrocyte
sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.
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antibodies recognising citrullinated vimentin.8 We previ-
ously found that anti-cTNC5 antibody positivity did
associate with smoking in the EIRA (Epidemiological
Investigation of Rheumatoid Arthritis) cohort; however,
this link was weaker than that observed for APCA
recognising citrullinated enolase.4 Here, we observed
that the ratio of ever smoker versus never-smoker, while
only slightly decreased in cTNC5-positive patients
(52.5%:47.5%), was substantially decreased in anti-
cTNC5 antibody-negative patients (60.7%:39.3%),
although no signiﬁcant association between anti-cTNC5
antibody status and smoking was observed. These data
suggest that further studies investigating whether
anti-cTNC5 antibody positivity could mark a serologically
distinct subset of people who will develop RA would be
of interest.
Finally, emerging evidence indicates that ACPA actively
contribute to inﬂammation, and can directly drive tissue
destruction that is the hallmark of established RA.
Uncovering the identity of peptides that give rise to
ACPA has started to reveal more about these mechan-
isms underlying disease pathogenesis. For example,
immune complexes containing anticitrullinated ﬁbrino-
gen antibodies signal to induce proinﬂammatory cyto-
kine synthesis, and antibodies to citrullinated vimentin
provoke osteoclastogenesis and bone erosion.9 10
However, little is known about the contribution of the
autoantibody response to the events that drive early
synovitis onto RA. Our ﬁnding that anti-cTNC5 anti-
bodies were raised only in people whose synovitis pro-
gressed to RA opens the door for further work
investigating whether these antibodies play a causal role
in driving the differentiation of early joint inﬂammation
towards persistent RA and away from disease resolution.
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